This randomized controlled trial from the Women's Health Initiative examined the effects of combined estrogen and progestin therapy on the incidence of peripheral arterial disease (PAD) in postmenopausal women. The study found no significant reduction in PAD risk among women receiving hormone therapy compared to those on a placebo, suggesting
